Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Exp Biol Med (Maywood). 2024 Jul 22;249:10121. doi: 10.3389/ebm.2024.10121. eCollection 2024.
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, having become a global public health problem, so the pathophysiological mechanisms and therapeutic strategies of CVDs need further study. Legumain is a powerful enzyme that is widely distributed in mammals and plays an important role in a variety of biological processes. Recent research suggests that legumain is associated with the occurrence and progression of CVDs. In this review, we provide a comprehensive overview of legumain in the pathogenesis of CVDs. The role of legumain in CVDs, such as carotid atherosclerosis, pulmonary hypertension, coronary artery disease, peripheral arterial disease, aortic aneurysms and dissection, is discussed. The potential applications of legumain as a biomarker of these diseases are also explored. By understanding the role of legumain in the pathogenesis of CVDs, we aim to support new therapeutic strategies to prevent or treat these diseases.
心血管疾病（CVDs）是全球范围内的主要死因，已成为一个全球性的公共卫生问题，因此需要进一步研究 CVDs 的病理生理机制和治疗策略。组织蛋白酶 L 是一种广泛存在于哺乳动物中的强大酶，在多种生物学过程中发挥着重要作用。最近的研究表明，组织蛋白酶 L 与 CVDs 的发生和发展有关。在这篇综述中，我们全面概述了组织蛋白酶 L 在 CVDs 发病机制中的作用。讨论了组织蛋白酶 L 在颈动脉粥样硬化、肺动脉高压、冠心病、外周动脉疾病、主动脉瘤和夹层等 CVDs 中的作用。还探讨了组织蛋白酶 L 作为这些疾病生物标志物的潜在应用。通过了解组织蛋白酶 L 在 CVDs 发病机制中的作用，我们旨在支持预防或治疗这些疾病的新治疗策略。
